Abstract:Patients with rheumatoid arthritis (RA) have a two to five times increased risk of developing premature cardiovascular disease that shortens life expectancy by 5-10 years. Traditional risk factors known to promote and accelerate the progression of atherosclerotic lesions however, are often absent in patients with RA. Many similarities have emerged between the paradigm of inflammation in the pathogenesis of atherosclerosis and the well-established mechanisms of inflammation in the pathogenesis of RA. Hence it is intriguing to speculate that inflammation in RA is not confined to the joints but also present in the vessel wall. Indeed, low-grade inflammation and endothelial dysfunction play pivotal roles in the initiation, progression and propagation of the atherosclerotic process. While the healthy endothelium prevents adhesion of mononuclear cells, the defence mechanisms cease under the influence of cardiovascular risk factors and inflammation and they express adhesion molecules (selectins, vascular adhesion molecule-([VCAM-]1, intercellular adhesion molecule-[ICAM-]1) that promote the adherence of monocytes. This expression is induced by pro-inflammatory cytokines such as interleukin-(IL-)1beta and tumor necrosis factor-(TNF-)alpha, by C-reactive protein (CRP), and CD40/CD40 ligand interactions. As all of these factors are present at increased levels in the systemic circulation in RA, it appears possible that they might impact the endothelium as well. Further similarities include proteolytic enzymes such as matrix metalloproteinases (MMPs) that play a role in joint destruction as well as in destabilization and rupture of vulnerable atherosclerotic plaques. In addition, coagulation factors such as increased levels of tissue factor (TF), van Willebrand factor (vWF) and plasminogen activator inhibitor-(PAI-)1 are important in both, RA and CAD. Endothelial dysfunction has shown to correlate with cardiovascular prognosis in several studies, which indicates its clinical relevance. Endothelial function measurement is performed in the coronary or peripheral circulation (by venous occlusion plethysmography or flow-mediated dilation). Recent studies have demonstrated impaired endothelial function in patients with RA, already at early stages of the disease. Similar results are found in patients with systemic lupus erythematosus (SLE), indicating that inflammation per se may impair altering vascular function. This and more evidence supports the notion that inflammation plays a pivotal role in vascular dysfunction and may by these mechanisms explain at least part of the excess morbidity and mortality observed in RA and SLE. In light of the growing evidence of increased cardiovascular morbidity and mortality mostly independent of traditional risk factors, treatment strategies in RA should not only aim at relieving symptoms and inhibiting joint destruction but should have a beneficial effect on the vasculature to reduce cardiovascular events. Indeed, an improvement in endothelial function in RA was recently demonstrated by anti-TNF-alpha therapy and statins. Whether and to what degree the effects of anti-inflammatory strategies to improve endothelial function, which although clinically well established is still a surrogate, translate into clinical benefit for our patients with rheumatologic diseases needs to be determined in large-scale clinical trials some of which are now already under way.

Abstract 129: Investigation of Atherosclerosis in Association with Arthritic Inflammation

Abstract 636: Accelerated Atherosclerosis in the Context of Rheumatoid Arthritis

Atherosclerotic plaque vulnerability is increased in mouse model of lupus

Cytokines and atherosclerosis: a comprehensive review of studies in mice

Changes in intestinal microbiota and phenotypes of immune cells in mice with atherosclerosis and arthritis

Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity

Protective Effect of Hydroxychloroquine on Rheumatoid Arthritis‐associated Atherosclerosis

Abstract: S4-17 EFFECTS OF MACROPHAGE ABCA7 DEFICIENCY ON LIPID METABOLISM AND THE DEVELOPMENT OF ATHEROSCLEROSIS IN LDL RECEPTOR KNOCKOUT MICE

Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass Cytometry.

Accelerated transformation of macrophage-derived foam cells in the presence of collagen-induced arthritis mice serum is associated with dyslipidemia

Cystatin C Influences the Autoimmune but Not Inflammatory Response to Cartilage Type Ii Collagen Leading to Chronic Arthritis Development

Collagen-induced Arthritis Mice Existed Endothelial Dysfunction ---- The New Evidence of Rheumatoid Arthritis Accelerated Atherosclerosis

Glycoprotein Acetyls Is a Novel Biomarker Predicting Cardiovascular Complications in Rheumatoid Arthritis

P1942A Trait of Inflammation Pathogenesis in Human Atherosclerosis: Inflammasome Driven Interleukin-1 Signaling in Complex Atherosclerotic Plaques Via Hyperlipidemia Trained Innate Immunity

Analysis of adipose tissues and stromal vascular cells in a murine arthritis model

Abstract: P1122 EFFECTS OF MACROPHAGE ABCA7 DEFICIENCY ON LIPID METABOLISM AND THE DEVELOPMENT OF ATHEROSCLEROSIS IN LDL RECEPTOR KNOCKOUT MICE

Mouse CD163 deficiency strongly enhances experimental collagen-induced arthritis

[Rheumatoid arthritis, inflammation, and atherosclerosis]

The Sera from Collagen-Induced Arthritis Mice Accelerate Macrophage-Derived Foam Cells Formation

Arthritis Development in Germ Free Mice Deficient for Reactive Oxygen Species

Protective Role of C3aR (c3a Anaphylatoxin Receptor) Against Atherosclerosis in Atherosclerosis-Prone Mice.